Aaron Ross Coleman
Next City
Contact Aaron
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Aaron:
All Hands on Deck to Prevent Displacement on Atlanta’s Westside
Not one, not two, not three, but four credit unions. → Read More
City Halls Now Hiring for Community Wealth Building
Intentionality is everything. → Read More
Data Shows How Doubters Are Wrong About Chicago Commercial Corridors
"Because of underdevelopment, that income travels." → Read More
Aerojet Rocketdyne shares drop 11% after offering $200 million in convertible notes
Shares of Aerojet Rocketdyne Holdings dropped 11 percent after the company announced $200 million private offering of convertible senior notes. → Read More
Aerojet Rocketdyne shares drop 11% after offering $200 million in convertible notes
Shares of Aerojet Rocketdyne Holdings dropped 11 percent after the company announced $200 million private offering of convertible senior notes. → Read More
Apple is the 'big test case' for Trump offshoring policy
Inside.com CEO Jason Calacanis told CNBC that "Apple is going to be the big test case" for Donald Trump's offshoring policy. → Read More
Autodesk shares drop more than 3% after disappointing guidance
Shares of Autodesk dropped more than 3 percent Wednesday, after the company reported disappointing guidance performance. → Read More
Urban Outfitters shares drop 12% after weak quarterly sales
Shares of Urban Outfitters were down following the retailer's announcement of weaker-than-expected quarterly sales. → Read More
Urban Outfitters shares drop 12% after weak quarterly sales
Shares of Urban Outfitters were down following the retailer's announcement of weaker-than-expected quarterly sales. → Read More
Juno Therapeutics plunges 24% after 2 more patients die during drug trial
Juno Therapeutics shares shed 24 percent Wednesday after the biopharmaceutical company announced complications with its Phase II clinical trial of JCAR015. → Read More
Juno Therapeutics plunges 24% after 2 more patients die during drug trial
Juno Therapeutics shares shed 24 percent Wednesday after the biopharmaceutical company announced complications with its Phase II clinical trial of JCAR015. → Read More
Shares of TubeMogul skyrocket after Adobe acquisition
Shares of TubeMogul skyrocketed in after-hours trading after it was announced that the ad-tech company was being acquired by software giant Adobe. → Read More
Trump victory puts rocket under global defense stocks
The shocking Donald Trump victory has put a rocket under defense stocks all over the world. → Read More
FMC shares soar 10% after third quarter results beat expectations
Shares of FMC jumped 10 percent after the company reported strong third-quarter earnings and raised its guidance. → Read More
FMC shares soar 10% after third quarter results beat expectations
Shares of FMC jumped 10 percent after the company reported strong third-quarter earnings and raised its guidance. → Read More
Trump lacks nuance, but speaks 'modicum of truth' about black America
While many have dismissed Trump's overtures to African-Americans as cynical, the GOP nominee has occasionally recognized real problems. → Read More
Cree shares shed 11% after underwhelming quarterly report
Shares of Cree fell 11 percent Wednesday following the company's underwhelming quarterly fiscal report. → Read More
Shares of Ulta Salon jumps after company raises guidance
Shares of Ulta Salon, Cosmetics & Fragrance jumped 11% Thursday, after the company raised its guidance for the third quarter and fiscal 2016. → Read More
New $10 million Harvard study to investigate racial hardships
U.S. policymakers need quality research if they are to address racial inequality, Harvard sociologist William Julius Wilson told CNBC on Thursday. → Read More
Snap plans limited rollout for Spectacles, report says
Snap is expected to conduct a "closed" rollout of new camera-mounted Spectacles, The Information reported. → Read More